Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) has received an average recommendation of “Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $52.57.
RXDX has been the subject of several recent research reports. SVB Leerink reissued an “outperform” rating on shares of Prometheus Biosciences in a research report on Thursday, May 12th. Zacks Investment Research upgraded shares of Prometheus Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, May 11th. BTIG Research started coverage on shares of Prometheus Biosciences in a report on Friday, February 11th. They issued a “buy” rating and a $62.00 price target on the stock. Wells Fargo & Company lifted their price target on shares of Prometheus Biosciences from $42.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, March 10th. Finally, Credit Suisse Group boosted their price objective on shares of Prometheus Biosciences from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, March 10th.
Institutional investors have recently modified their holdings of the business. Citigroup Inc. raised its position in shares of Prometheus Biosciences by 140.2% in the third quarter. Citigroup Inc. now owns 1,290 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 753 shares during the period. Nisa Investment Advisors LLC acquired a new position in shares of Prometheus Biosciences during the 1st quarter worth about $31,000. Royal Bank of Canada raised its position in shares of Prometheus Biosciences by 116.9% during the 3rd quarter. Royal Bank of Canada now owns 1,677 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 904 shares during the last quarter. Morgan Stanley raised its position in shares of Prometheus Biosciences by 888.2% during the 2nd quarter. Morgan Stanley now owns 2,856 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 2,567 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Prometheus Biosciences during the 1st quarter worth about $86,000. Institutional investors and hedge funds own 65.41% of the company’s stock.
NASDAQ:RXDX opened at $27.81 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.56 and a quick ratio of 13.56. Prometheus Biosciences has a 1-year low of $19.79 and a 1-year high of $51.96. The company has a 50-day moving average of $30.60 and a 200 day moving average of $35.05. The firm has a market cap of $1.09 billion, a PE ratio of -10.00 and a beta of 2.64.
Prometheus Biosciences (NASDAQ:RXDX – Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.04). Prometheus Biosciences had a negative net margin of 1,722.58% and a negative return on equity of 43.92%. Sell-side analysts anticipate that Prometheus Biosciences will post -3.6 EPS for the current fiscal year.
Prometheus Biosciences Company Profile (Get Rating)
Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease.